ConserV is a late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. We have a pipeline of eight vaccines in pre-clinical and clinical development including broad-spectrum influenza*, broad-spectrum coronavirus, mosquito-borne diseases*, HIV, Hepatitis C, Hepatitis B, Rotavirus and Chagas. ConserV’s USP is the identification of antigens consisting of conserved regions of viral proteins containing a high number of REACTIVE T-cell epitopes with extensive HLA coverage.
*Sub-licensed to Imutex Limited, a 51% owned subsidiary. hVIVO Services Limited own 49% of Imutex.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 77 Heyford Park, Bicester,ox25 5hd,united Kingdom
- Industry
- Biotechnology
- Website
- http://conservbio.com
- Keywords
- antigen, mRNA, peptides, vaccine, adjuvant, broad-spectrum, collaboration, influenza, HIV, coronavirus, mosquito, hepatitis, ratovirus, RSV, MHC Class I, MHC Class II, antibodies, Chagas, malaria, denge, zika.
- HQ
- Bicester
Conserv Bioscience Questions
Conserv Bioscience's website is http://conservbio.com
Conserv Bioscience's LinkedIn profile is https://uk.linkedin.com/company/conserv-bioscience
Conserv Bioscience has
7 employees.
View email and phone details for 7
employees at Conserv Bioscience.
Conserv Bioscience's industry is
Biotechnology
Conserv Bioscience's top competitors are
Integrated Commercialization Solutions, Inc.,
Nikalyte Ltd,
Cell Origin, Llc,
Conserv Metálica,
Lymphogenix,
Prep Biopharm,
Capo Therapeutics, Inc.,
Barinthus Biotherapeutics,
Infinitopes,
Diosynvax.
Conserv Bioscience's categories are Biotechnology
Conserv Bioscience's founding year is 2020
